|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/16/23 ENDRA Life Sciences Inc. S-8 3/16/23 4:73K Blueprint/FA |
Document/Exhibit Description Pages Size
1: S-8 Registration Statement - Securities for an HTML 42K
Employee Benefit Plan
2: EX-5.1 Opinion of K&L Gates LLP HTML 11K
3: EX-23.1 Consent of Expert or Counsel HTML 5K
4: EX-FILING FEES Filing Fees HTML 14K
| Page | (sequential) | (alphabetic) | ↑Top | ||
|---|---|---|---|---|---|
| 1 | 1st Page – Filing Submission | ||||
| " | 24.1 | ||||
| " | Power of Attorney (included on the signature page of this Registration Statement) | ||||
As filed with the Securities and Exchange Commission on March 16, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
| ENDRA LIFE SCIENCES INC. |
|
(Exact name of registrant as specified in its charter) |
| Delaware |
| 26-0579295 |
| (State or other jurisdiction of incorporation or organization) |
| (I.R.S. Employer Identification No.) |
|
|
|
|
| 3600 Green Court, Suite 350 |
| |
| (Address of principal executive offices) |
| (Zip Code) |
ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan
(Full title of the plan)
Chief Executive Officer
ENDRA Life Sciences Inc.
3600 Green Court, Suite 350
(Name and address of agent for service)
(734) 335-0468
(Telephone number, including area code,
of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|
|
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed to register an additional 867,966 shares of Common Stock under the ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan, as amended (the “Plan”), as a result of an evergreen provision in the Plan providing that the total number of shares of Common Stock reserved for issuance under the Plan is automatically increased as of each January 1.
These additional shares of Common Stock are securities of the same class as other securities for which the Registration Statements on Form S-8 (File Nos. 333-218894, 333-233178, 333-237415, 333-254713 and 333-263992) (the “Prior Registration Statements”) were filed with the Securities and Exchange Commission (the “Commission”) on June 21, 2017, August 9, 2019, March 26, 2020, March 25, 2021 and March 30, 2022, respectively. In accordance with Instruction E of Form S-8, the content of the Prior Registration Statements is incorporated herein by reference and made a part of this Registration Statement on Form S-8.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1. Plan Information.
The information required by this Item 1 is omitted from this registration statement in accordance with Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”), and the Note to Part I of Form S-8.
Item 2. Registrant Information and Employee Plan Annual Information.
The information required by this Item 2 is omitted from this registration statement in accordance with Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8.
| 2 |
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents have been filed by ENDRA Life Sciences Inc. (the “Registrant”) with the Commission and are incorporated herein by reference:
| · | Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on March 16, 2023; and |
|
|
|
| · | The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form S-1, originally filed with the Commission on November 21, 2016, as amended (File No. 333-214724), which description is incorporated by reference into the Registrant’s Registration Statement on Form 8-A, originally filed with the Commission pursuant to Section 12(g) of the Exchange Act on December 16, 2016 (File No. 001-37969), including any further amendment or report filed hereafter for the purpose of updating such description. |
All reports and other documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof, and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. The Registrant is not incorporating by reference any reports or documents or portions thereof that are not considered to be “filed” with the Commission.
Any statement contained herein or in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated herein by reference modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
| 3 |
Item 8. Exhibits.
| Exhibit Number |
| Description |
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| ||
|
|
|
|
|
| Consent of RBSM LLP, Independent Registered Public Accounting Firm | |
|
|
|
|
|
| ||
|
|
|
|
|
| Power of Attorney (included on the signature page of this Registration Statement) | |
|
|
|
|
|
|
* - Filed herewith
| 4 |
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ann Arbor, State of Michigan, on March 16, 2023.
| ENDRA Life Sciences Inc. | |||
| By: | /s/ Francois Michelon | ||
|
|
| Francois Michelon | |
| Chief Executive Officer | |||
Each person whose signature appears below constitutes and appoints Francois Michelon and Irina Pestrikova, and each of them, his/her true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, severally, for him/her and in his/her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney may be executed in counterparts.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities indicated, in each case on March 16, 2023:
| Signature | Title |
| |
|
|
|
|
|
| Chief Executive Officer and Director |
| ||
| (Principal Executive Officer) |
| ||
|
| |||
| /s/ Irina Pestrikova | Senior Director of Finance |
| |
| (Principal Financial Officer and Principal Accounting Officer) |
| ||
|
| |||
| Director |
| ||
|
| |||
|
| |||
| Director |
| ||
|
| |||
|
| |||
| /s/ Michael Harsh | Director |
| |
|
| |||
|
| |||
| /s/ Alexander Tokman | Director |
| |
|
|
| 5 |
| This ‘S-8’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / Effective on: | 3/16/23 | 10-K | ||
| 12/31/22 | 10-K | |||
| 3/30/22 | 10-K, 4, 424B5, 8-K, S-8 | |||
| 3/25/21 | 10-K, 4, 8-K, S-3, S-8 | |||
| 3/26/20 | 10-K, 8-K, S-8 | |||
| 8/9/19 | S-8 | |||
| 6/21/17 | 10-Q, S-8 | |||
| 12/16/16 | 8-A12B, S-1/A | |||
| 11/21/16 | DRS, DRS/A, S-1 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/08/22 ENDRA Life Sciences Inc. 8-K:5,9 12/08/22 13:159K Blueprint/FA 6/18/20 ENDRA Life Sciences Inc. 8-K:5,9 6/16/20 2:54K Blueprint/FA 5/10/18 ENDRA Life Sciences Inc. DEF 14A 6/12/18 1:985K EdgarAgents LLC/FA 5/12/17 ENDRA Life Sciences Inc. 8-K:5,9 5/08/17 6:209K Blueprint/FA 12/06/16 ENDRA Life Sciences Inc. S-1/A 12:2.9M Blueprint/FA |